PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
10.36%
Positive revenue growth while AVGO is negative. John Neff might see a notable competitive edge here.
17.05%
Gross profit growth above 1.5x AVGO's 5.31%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
41.52%
EBIT growth above 1.5x AVGO's 15.11%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
42.32%
Operating income growth above 1.5x AVGO's 15.11%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
40.25%
Net income growth above 1.5x AVGO's 17.91%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
43.18%
EPS growth above 1.5x AVGO's 16.67%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
40.91%
Diluted EPS growth above 1.5x AVGO's 15.09%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-0.93%
Share reduction while AVGO is at 0.80%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.91%
Reduced diluted shares while AVGO is at 1.18%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
0.31%
Dividend growth under 50% of AVGO's 8.80%. Michael Burry might suspect more pressing needs for cash or weaker earnings power.
67.75%
OCF growth above 1.5x AVGO's 9.61%. David Dodd would confirm a clear edge in underlying cash generation.
80.52%
FCF growth above 1.5x AVGO's 0.56%. David Dodd would verify if the firm’s strategic investments yield superior returns.
67.30%
10Y revenue/share CAGR at 75-90% of AVGO's 83.90%. Bill Ackman would press for new markets or product lines to narrow the gap.
58.50%
5Y revenue/share CAGR at 50-75% of AVGO's 83.90%. Martin Whitman would worry about a lagging mid-term growth trajectory.
2.76%
3Y revenue/share CAGR under 50% of AVGO's 22.19%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
152.27%
10Y OCF/share CAGR at 50-75% of AVGO's 224.24%. Martin Whitman might fear a structural deficiency in operational efficiency.
64.60%
Below 50% of AVGO's 224.24%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
32.57%
Positive 3Y OCF/share CAGR while AVGO is negative. John Neff might see a big short-term edge in operational efficiency.
155.09%
Below 50% of AVGO's 534.55%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
210.77%
Below 50% of AVGO's 534.55%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
9.70%
3Y net income/share CAGR 50-75% of AVGO's 14.24%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
38.59%
Below 50% of AVGO's 254.76%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
34.39%
Below 50% of AVGO's 254.76%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
3.61%
Below 50% of AVGO's 71.89%. Michael Burry suspects a serious short-term disadvantage in building book value.
1337.84%
Dividend/share CAGR of 1337.84% while AVGO is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
174.90%
Dividend/share CAGR of 174.90% while AVGO is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
132.42%
3Y dividend/share CAGR at 50-75% of AVGO's 231.87%. Martin Whitman might see a weaker short-term approach to distributing cash.
12.69%
Our AR growth while AVGO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
1.75%
Inventory shrinking or stable vs. AVGO's 5.24%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
-5.94%
Negative asset growth while AVGO invests at 5.73%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-0.53%
We have a declining book value while AVGO shows 4.57%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-17.76%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-4.64%
Our R&D shrinks while AVGO invests at 6.54%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-1.46%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.